{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-041721","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2024-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.334209+00:00","generated_at":"2026-05-30T12:22:24.541696+00:00","sec_items":["1.01","3.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"bioAffinity prices $2.66M registered direct offering and concurrent private placement of common stock and warrants","bullets":["Offering includes 2,048,294 shares at $1.30 per share and warrants to buy up to 2,662,782 shares at $1.50.","Gross proceeds expected ~$2.66M; closing on or about Oct. 21, 2024; WallachBeth Capital acting as placement agent (8% fee).","Warrants exercisable upon stockholder approval and expire in five years; officers/directors subject to 60-day lock-up.","Bylaws amended to set quorum at 34% of outstanding shares entitled to vote, effective Oct. 17, 2024.","Shares offered under effective S-3 shelf; warrants issued in private placement exempt from registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-041721","json":"https://secwatch.observer/filing/0001493152-24-041721.json","markdown":"https://secwatch.observer/filing/0001493152-24-041721.md","text":"https://secwatch.observer/filing/0001493152-24-041721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224041721/0001493152-24-041721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224041721/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:22:24.541696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b9a8574260815ac0906e3a0de29aac726c89317","claim":"bioAffinity Technologies, Inc.: Amended quorum requirement to 34% of outstanding shares entitled to vote (effective 2024-10-17).","evidence_excerpt":"On October 17, 2024, the Board amended the Company’s Amended and Restated By-Laws, effective October 17, 2024, in order to amend the quorum requirement of Article II, Section 2.07 of the Amended and Restated By-Laws, such that thirty-four percent (34%) of the outstanding shares of stock of the Company entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224041721/0001493152-24-041721-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-10-17"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}